Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Anderson

Showing results (131-140 of 271) with videos related to

Pageof 28
Sort By:
Emerging Infectious Diseases|November 21, 2018
Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men<sup>1</sup>Martin Hoenigl, Sonia Jain, David Moore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 6, 2018
Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048Albert Y Liu, Jingyang Zhang, Peter L Anderson, et al.
Journal of the International AIDS Society|May 20, 2025
No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 studyAkarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen Kerr, et al.
Open Forum Infectious Diseases|October 19, 2020
Income Inequality Is Associated With Low Cumulative Antiretroviral Adherence in Persons With Human Immunodeficiency VirusFrances Vernon, Mary Morrow, Samantha MaWhinney, et al.
Plos One|January 15, 2014
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP)Albert Y Liu, Qiyun Yang, Yong Huang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 17, 2020
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS StudyJenna Yager, Jose Castillo-Mancilla, Mustafa E Ibrahim, et al.
AIDS (London, England)|September 5, 2021
Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarateJenna L Yager, Kristina M Brooks, Jose R Castillo-Mancilla, et al.
Antiviral Research|September 27, 2024
Evaluation of pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in pregnant and postpartum women in South Africa: PrEP-PP PK studyDvora Joseph Davey, Sumaya Dadan, Kalisha Bheemraj, et al.
International Journal of Pharmaceutics|July 15, 2020
Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applicationsAntons Sizovs, Fernanda P Pons-Faudoa, Gulsah Malgir, et al.
The Journal of Antimicrobial Chemotherapy|January 23, 2019
Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapyKatherine Frasca, Mary Morrow, Ryan P Coyle, et al.
Pageof 28

Showing results (131-140 of 271) with videos related to

Sort By:
Pageof 28
Emerging Infectious Diseases|November 21, 2018
Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men<sup>1</sup>Martin Hoenigl, Sonia Jain, David Moore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 6, 2018
Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048Albert Y Liu, Jingyang Zhang, Peter L Anderson, et al.
Journal of the International AIDS Society|May 20, 2025
No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 studyAkarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen Kerr, et al.
Open Forum Infectious Diseases|October 19, 2020
Income Inequality Is Associated With Low Cumulative Antiretroviral Adherence in Persons With Human Immunodeficiency VirusFrances Vernon, Mary Morrow, Samantha MaWhinney, et al.
Plos One|January 15, 2014
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP)Albert Y Liu, Qiyun Yang, Yong Huang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 17, 2020
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS StudyJenna Yager, Jose Castillo-Mancilla, Mustafa E Ibrahim, et al.
AIDS (London, England)|September 5, 2021
Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarateJenna L Yager, Kristina M Brooks, Jose R Castillo-Mancilla, et al.
Antiviral Research|September 27, 2024
Evaluation of pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in pregnant and postpartum women in South Africa: PrEP-PP PK studyDvora Joseph Davey, Sumaya Dadan, Kalisha Bheemraj, et al.
International Journal of Pharmaceutics|July 15, 2020
Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applicationsAntons Sizovs, Fernanda P Pons-Faudoa, Gulsah Malgir, et al.
The Journal of Antimicrobial Chemotherapy|January 23, 2019
Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapyKatherine Frasca, Mary Morrow, Ryan P Coyle, et al.
Pageof 28